O	0	1	A
O	2	12	randomised
O	13	18	study
O	19	21	of
B-intervention	22	30	tailored
I-intervention	31	39	toxicity
I-intervention	39	40	-
I-intervention	40	45	based
I-intervention	46	52	dosage
I-intervention	53	55	of
I-intervention	56	68	fluorouracil
I-intervention	68	69	-
I-intervention	69	79	epirubicin
I-intervention	79	80	-
I-intervention	80	96	cyclophosphamide
I-intervention	97	109	chemotherapy
O	110	113	for
O	114	119	early
O	120	126	breast
O	127	133	cancer
O	134	135	(
O	135	138	SBG
O	139	143	2000
O	143	144	-
O	144	145	1
O	145	146	)
O	146	147	.

O	148	161	Retrospective
O	162	169	studies
O	170	174	have
O	175	187	demonstrated
O	188	189	a
O	190	195	worse
O	196	203	outcome
O	204	206	in
O	207	213	breast
O	214	220	cancer
O	221	229	patients
O	230	233	not
O	234	244	developing
O	245	255	leukopenia
O	256	262	during
O	263	271	adjuvant
O	272	284	chemotherapy
O	284	285	.

O	286	289	The
O	290	293	SBG
O	294	298	2000
O	298	299	-
O	299	300	1
O	301	303	is
O	304	307	the
O	308	313	first
O	314	324	randomised
O	325	330	trial
O	331	339	designed
O	340	342	to
O	343	350	compare
O	351	363	individually
O	364	369	dosed
O	370	382	chemotherapy
O	383	390	without
O	391	392	G
O	392	393	-
O	393	396	CSF
O	397	404	support
O	405	410	based
O	411	413	on
O	414	419	grade
O	420	422	of
O	423	431	toxicity
O	432	434	to
O	435	443	standard
O	443	444	-
O	444	449	dosed
O	450	462	chemotherapy
O	463	468	based
O	469	471	on
O	472	476	body
O	477	484	surface
O	485	489	area
O	490	491	(
O	491	494	BSA
O	494	495	)
O	495	496	.

B-eligibility	497	505	Patients
I-eligibility	506	510	with
I-eligibility	511	516	early
I-eligibility	517	523	breast
I-eligibility	524	530	cancer
O	531	535	were
O	536	544	included
O	545	548	and
O	549	557	received
O	558	561	the
O	562	567	first
O	568	573	cycle
O	574	576	of
O	577	585	standard
O	586	589	FEC
O	590	591	(
O	591	603	fluorouracil
O	604	607	600
O	608	610	mg
O	610	611	/
O	611	613	m2
O	613	614	,
O	615	625	epirubicin
O	626	628	60
O	629	631	mg
O	631	632	/
O	632	634	m2
O	634	635	,
O	636	652	cyclophosphamide
O	653	656	600
O	657	659	mg
O	659	660	/
O	660	662	m2
O	662	663	)
O	663	664	.

O	665	673	Patients
O	674	678	with
O	679	684	nadir
O	685	695	leukopenia
O	696	701	grade
O	702	703	0
O	703	704	-
O	704	705	2
O	706	711	after
O	712	717	first
O	718	723	cycle
O	724	728	were
O	729	739	randomised
O	740	747	between
O	748	754	either
O	755	756	6
O	757	767	additional
O	768	775	courses
O	776	778	of
O	779	787	tailored
O	788	791	FEC
O	792	796	with
O	797	806	increased
O	807	812	doses
O	813	814	(
O	814	815	E
O	816	818	75
O	818	819	-
O	819	821	90
O	822	824	mg
O	824	825	/
O	825	827	m2
O	827	828	,
O	829	830	C
O	831	834	900
O	834	835	-
O	835	839	1200
O	840	842	mg
O	842	843	/
O	843	845	m2
O	845	846	)
O	847	849	or
O	850	855	fixed
O	856	865	treatment
O	866	870	with
B-control	871	872	6
I-control	873	881	standard
I-control	882	885	FEC
O	885	886	.

O	887	895	Patients
O	896	900	with
O	901	906	grade
O	907	908	3
O	908	909	-
O	909	910	4
O	911	921	leukopenia
O	922	926	were
O	927	937	registered
O	938	941	and
O	942	949	treated
O	950	954	with
O	955	956	6
O	957	965	standard
O	966	969	FEC
O	969	970	.

O	971	978	Primary
O	979	982	end
O	982	983	-
O	983	988	point
O	989	992	was
B-outcome-Measure	993	1000	distant
I-outcome-Measure	1001	1008	disease
I-outcome-Measure	1008	1009	-
I-outcome-Measure	1009	1013	free
I-outcome-Measure	1014	1022	survival
I-outcome-Measure	1023	1024	(
I-outcome-Measure	1024	1028	DDFS
I-outcome-Measure	1028	1029	)
O	1029	1030	.

O	1031	1034	The
O	1035	1040	study
O	1041	1049	enrolled
B-total-participants	1050	1054	1535
O	1055	1063	patients
O	1063	1064	,
O	1065	1067	of
O	1068	1073	which
B-total-participants	1074	1078	1052
O	1079	1087	patients
O	1088	1092	were
O	1093	1103	randomised
O	1104	1106	to
O	1107	1115	tailored
O	1116	1119	FEC
O	1120	1121	(
O	1121	1122	N
O	1123	1124	=
B-intervention-participants	1125	1128	524
O	1128	1129	)
O	1130	1132	or
O	1133	1141	standard
O	1142	1145	FEC
O	1146	1147	(
O	1147	1148	N
O	1149	1150	=
B-control-participants	1151	1154	528
O	1154	1155	)
O	1155	1156	,
O	1157	1164	whereas
O	1165	1168	401
O	1169	1177	patients
O	1178	1182	with
O	1183	1193	leukopenia
O	1194	1199	grade
O	1200	1201	3
O	1201	1202	-
O	1202	1203	4
O	1204	1213	continued
O	1214	1222	standard
O	1223	1226	FEC
O	1227	1230	and
O	1231	1237	formed
O	1238	1241	the
O	1242	1252	registered
O	1253	1259	cohort
O	1259	1260	.

O	1261	1265	Dose
O	1266	1276	escalation
O	1277	1280	did
O	1281	1284	not
O	1285	1298	statistically
O	1299	1312	significantly
O	1313	1320	improve
B-outcome	1321	1323	10
I-outcome	1323	1324	-
I-outcome	1324	1328	year
I-outcome	1329	1333	DDFS
O	1334	1335	(
B-iv-bin-percent	1335	1337	79
I-iv-bin-percent	1337	1338	%
O	1339	1342	and
B-cv-bin-percent	1343	1345	77
I-cv-bin-percent	1345	1346	%
O	1346	1347	,
O	1348	1350	HR
O	1351	1352	0
O	1352	1353	.
O	1353	1355	87
O	1355	1356	,
O	1357	1359	CI
O	1360	1361	0
O	1361	1362	.
O	1362	1364	67
O	1364	1365	-
O	1365	1366	1
O	1366	1367	.
O	1367	1369	14
O	1369	1370	,
O	1371	1372	P
O	1373	1374	=
O	1375	1376	0
O	1376	1377	.
O	1377	1379	32
O	1379	1380	)
O	1381	1383	or
B-outcome	1384	1386	OS
O	1387	1388	(
B-iv-bin-percent	1388	1390	82
I-iv-bin-percent	1390	1391	%
O	1392	1395	and
B-cv-bin-percent	1396	1398	78
I-cv-bin-percent	1398	1399	%
O	1399	1400	,
O	1401	1413	respectively
O	1413	1414	,
O	1415	1417	HR
O	1418	1419	0
O	1419	1420	.
O	1420	1422	89
O	1422	1423	,
O	1424	1426	CI
O	1427	1428	0
O	1428	1429	.
O	1429	1431	57
O	1431	1432	-
O	1432	1433	1
O	1433	1434	.
O	1434	1436	16
O	1436	1437	,
O	1438	1439	P
O	1440	1441	=
O	1442	1443	0
O	1443	1444	.
O	1444	1446	38
O	1446	1447	)
O	1447	1448	.

O	1449	1462	Corresponding
O	1463	1472	estimates
O	1473	1476	for
O	1477	1480	the
O	1481	1491	registered
O	1492	1497	group
O	1498	1500	of
O	1501	1509	patients
O	1510	1514	were
B-outcome	1515	1519	DDFS
B-iv-bin-percent	1520	1522	79
I-iv-bin-percent	1522	1523	%
O	1524	1527	and
B-outcome	1528	1530	OS
B-iv-bin-percent	1531	1533	82
I-iv-bin-percent	1533	1534	%
O	1534	1535	,
O	1536	1548	respectively
O	1548	1549	.

O	1550	1553	The
O	1554	1557	SBG
O	1558	1562	2000
O	1562	1563	-
O	1563	1564	1
O	1565	1570	study
O	1571	1577	failed
O	1578	1580	to
O	1581	1585	show
O	1586	1587	a
O	1588	1601	statistically
O	1602	1613	significant
O	1614	1625	improvement
O	1626	1628	of
O	1629	1638	escalated
O	1639	1642	and
O	1643	1651	tailored
O	1651	1652	-
O	1652	1657	dosed
O	1658	1670	chemotherapy
O	1671	1679	compared
O	1680	1684	with
O	1685	1693	standard
O	1694	1697	BSA
O	1697	1698	-
O	1698	1703	based
O	1704	1716	chemotherapy
O	1717	1719	in
O	1720	1728	patients
O	1729	1733	with
O	1734	1737	low
O	1738	1752	haematological
O	1753	1761	toxicity
O	1761	1762	,
O	1763	1771	although
O	1772	1775	all
O	1776	1784	efficacy
O	1785	1795	parameters
O	1796	1802	showed
O	1803	1804	a
O	1805	1814	numerical
O	1815	1824	advantage
O	1825	1828	for
O	1829	1837	tailored
O	1838	1847	treatment
O	1847	1848	.
